Traws Pharma
TRAW
16 hedge funds and large institutions have $18.7M invested in Traws Pharma in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
6% less funds holding
Funds holding: 17 → 16 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
51% less capital invested
Capital invested by funds: $38.2M → $18.7M (-$19.5M)
87% less call options, than puts
Call options by funds: $3K | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$3.61M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.81M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.2M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$1.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.22M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$3.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.41M |
| 4 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$2.03M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
51
Globeflex Capital
San Diego,
California
| – | -$2K | – | – |
|
52
Invesco
Atlanta,
Georgia
| – | -$115K | – | – |
|
|
KPCM
53
Kings Point Capital Management
Great Neck,
New York
| – | -$63K | – | – |
|
|
SIM
54
SSI Investment Management
Los Angeles,
California
| – | -$247K | – | – |
|
|
SB
55
Suntrust Banks
Atlanta,
Georgia
| – | -$192K | – | – |
|
|
TAM
56
Tocqueville Asset Management
New York
| – | -$232K | – | – |
|
|
VKH
57
Virtu KCG Holdings
New York
| – | -$143K | – | – |
|
TRAW Hedge Fund Activity: Q1 2014 in Review
16 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2014, worth a combined $18.7M — down 51% from $38.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TRAW and 7 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sarissa Capital Management, opening a new position worth an estimated $3.61M. The largest seller was Emerald Advisers, exiting entirely with an estimated $4.22M sold.
- 16 institutional investors held Traws Pharma (TRAW) as of Q1 2014, down from 17 in Q4 2013.
- Funds reported $18.7M of Traws Pharma stock for Q1 2014, down 51% quarter-over-quarter.
- 7 funds opened new Traws Pharma positions in Q1 2014 and 8 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q1 2014 was Sarissa Capital Management, an estimated $3.61M added.
- The largest Traws Pharma seller in Q1 2014 was Emerald Advisers, an estimated $4.22M sold.
Based on aggregated 13F filings for Q1 2014.